TAF/FTC — Competitive Intelligence Brief

TAF/FTC (TAF/FTC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor combination. Area: Infectious Disease / Virology.

marketed Nucleoside reverse transcriptase inhibitor combination HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

TAF/FTC (TAF/FTC) — Göteborg University. TAF/FTC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TAF/FTC TARGET	TAF/FTC	Göteborg University	marketed	Nucleoside reverse transcriptase inhibitor combination	HIV reverse transcriptase
Atripla (r)	Atripla (r)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase
FTC-TDF PrEP	FTC-TDF PrEP	University of Washington	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV reverse transcriptase
Biktarvy 50/200/25 Tab	Biktarvy 50/200/25 Tab	Radboud University Medical Center	marketed	Antiretroviral combination (integrase inhibitor + nucleotide/nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
Tenofovir alafenamide/emtricitabine	Tenofovir alafenamide/emtricitabine	ViiV Healthcare	marketed	Nucleotide/nucleoside reverse transcriptase inhibitor combination	HIV reverse transcriptase
zidovudine+lamivudine+lopinavir/ritonavir	zidovudine+lamivudine+lopinavir/ritonavir	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase and HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor combination class)

1. Göteborg University · 1 drug in this class